Study details
Enrolling now
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
Laureate Institute for Brain Research, Inc.
NCT IDNCT06004115ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
165
Study length
about 4.1 years
Ages
18–65
Locations
1 site in OK
About this study
This trial is testing whether the way people process threats in their brains differs between those with anxiety and depression, and how this affects their response to an anti-anxiety drug. It uses brain imaging to compare threat processing in individuals with comorbid anxiety and depression versus those with just depression or just anxiety.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Lorazepam
PhasePhase 4
DrugLorazepam
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
lorazepam
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health